$0.24
-0.01 (-4.00%)
USD · as of 2026-08-17 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where LYRA is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 4 with posted results
Held by 0 tracked-famous managers · FINRA short interest 1.7 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)NCT05295459results2026-02-19Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal PolypsRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LYR-210, Sham procedure control · Other: Background therapy | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 182 | 2025-04-02actual | 2026-02-19 |
| Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in AdultsNCT05219968results2025-05-02Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: LYR-210, Sham procedure control · Other: Background Therapy | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 196 | 2024-03-04actual | 2025-05-02 |
| LYR-220 for Adult Subjects With Chronic Rhinosinusitis (BEACON Study)NCT05035654results2024-12-17Product-related Unexpected Serious Adverse EventsRandomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LYR-220 Design 1 (Part 1 only), LYR-220 Design 2 (Part 1 and Part 2), Bilateral sham procedure control (Part 2) | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 48 | 2023-08-30actual | 2024-12-17 |
| LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis (LANTERN Study)NCT04041609results2023-06-06Change From Baseline (CFBL) in Chronic Sinusitis Symptom Scores at Week 4Randomized · Single-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: LYR-210 · Other: Sham comparator | Chronic Sinusitis, Chronic Rhinosinusitis (Diagnosis) | 71 | 2020-03-25actual | 2023-07-25 |
| 480 Biomedical Sinus Drug DepotNCT02967731Product related serious adverse events from baseline visit to 4 weeks post procedureOpen-label · Treatment | Phase 1 | Completed | Drug: 480 Mometasone Furoate Sinus Drug Depot | Chronic Sinusitis | 20 | 2017-12-19actual | 2021-08-25 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19